![Too many targets, not enough patients: rethinking neuroblastoma clinical trials | Nature Reviews Cancer Too many targets, not enough patients: rethinking neuroblastoma clinical trials | Nature Reviews Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41568-018-0003-x/MediaObjects/41568_2018_3_Fig1_HTML.jpg)
Too many targets, not enough patients: rethinking neuroblastoma clinical trials | Nature Reviews Cancer
![TRANSATLANTIC CLINICAL TRIAL FOR CHILDREN WITH NEUROBLASTOMA IS OPEN FOR ENROLLMENT IN THE U.K. - SOON TO OPEN IN THE U.S. AND GERMANY - Band of Parents TRANSATLANTIC CLINICAL TRIAL FOR CHILDREN WITH NEUROBLASTOMA IS OPEN FOR ENROLLMENT IN THE U.K. - SOON TO OPEN IN THE U.S. AND GERMANY - Band of Parents](https://www.bandofparents.org/wp-content/uploads/2018/06/Collaborative-Research-FB.png)
TRANSATLANTIC CLINICAL TRIAL FOR CHILDREN WITH NEUROBLASTOMA IS OPEN FOR ENROLLMENT IN THE U.K. - SOON TO OPEN IN THE U.S. AND GERMANY - Band of Parents
CCF on Twitter: "Around 40 children are diagnosed with Neuroblastoma each year. Our funding of the SIOPEN Neuroblastoma Clinical Trials at #ANZCHOG will help identify better therapies and give hope to these
![Intellasia East Asia News - Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma Intellasia East Asia News - Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma](https://mms.businesswire.com/media/20220110005490/en/694651/5/aptorum_hori_HQ.jpg)
Intellasia East Asia News - Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
![Results of a prospective clinical trial JN‐L‐10 using image‐defined risk factors to inform surgical decisions for children with low‐risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee - Results of a prospective clinical trial JN‐L‐10 using image‐defined risk factors to inform surgical decisions for children with low‐risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee -](https://www.onlinelibrary.wiley.com/cms/asset/d4e7fd2f-d304-4c72-a6ef-8de2ad2fc695/pbc.v66.11.cover.jpg)
Results of a prospective clinical trial JN‐L‐10 using image‐defined risk factors to inform surgical decisions for children with low‐risk neuroblastoma disease: A report from the Japan Children's Cancer Group Neuroblastoma Committee -
![Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma - European Journal Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma - European Journal](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/c6e7b5df-5edf-4431-8121-ba97c1b46289/gr1.jpg)
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma - European Journal
![A groundbreaking clinical trial for children with aggressive neuroblastoma - Cancer Research UK - Cancer news A groundbreaking clinical trial for children with aggressive neuroblastoma - Cancer Research UK - Cancer news](https://news.cancerresearchuk.org/wp-content/uploads/2019/09/child_development_hero.jpg)